News

Adults with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) who have trouble breathing at rest or with light activity may benefit from a procedure called respiratory rate modulation, a pilot, single-center study shows. The three-month procedure also led to lower symptom severity and decreased respiratory…

OxiWear has raised $1.25 million in funding to support the final steps in the commercialization of its ear-wearable device, designed to continuously monitor blood oxygen levels in people with pulmonary hypertension (PH). The funding round, initially with a target of $750,000, was well “oversubscribed,” the company reported in…

Bilateral lung transplant rapidly and effectively normalizes right ventricular function of the heart in children with severe pulmonary arterial hypertension (PAH) and heart failure, a study reports. These benefits in the 15 children evaluated were also independent of a child’s age, weight, and right ventricular (RV) impairment before the transplant. Given…

Treatment with the experimental medication KER-012 helped to prevent heart damage in a mouse model of pulmonary hypertension, new research shows. The findings were showcased by KER-012’s developer, Keros Therapeutics, at the American Heart Association (AHA) 2021 Scientific Sessions, held Nov. 13–15, according to a company press…

Low birth weight has been linked to an increased risk of pulmonary hypertension (PH) in premature infants needing oxygen therapy for at least 28 days, an analysis revealed. Additionally, the failure, after birth, of the blood vessels of the heart to close — before birth, they’re normally open to…

A large proportion of Swedish children younger than 7 who were diagnosed with pulmonary hypertension (PH) started treatment with vasodilators before age 1, and almost all of those treated received Revatio (sildenafil) as a first therapy, according to an analysis of a nationwide prescription registry. Despite treatment, mortality…

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Yutrepia (treprostinil), previously known as LIQ861, as an inhalation treatment for pulmonary arterial hypertension (PAH), its developer Liquidia announced. Tentative approval means that Yutrepia has met all regulatory standards regarding quality, safety, and efficacy required for approval in the U.S. Because…

Local anesthesia is better than general anesthesia for both the mother and her baby when delivery is by cesarean section (C-section) and the woman has pulmonary arterial hypertension (PAH), a study suggests. These findings might help to guide doctors in selecting the best approach to anesthesia for women in labor.

Circulating endostatin, a protein that inhibits new blood vessel formation, appears to correlate well with mortality and disease severity in people with pulmonary arterial hypertension (PAH) in a large, observational study. Blood levels of endostatin show a “clear potential … as a robust prognostic biomarker in PAH” and could…

People with chronic thromboembolic pulmonary hypertension (CTEPH) have significantly worse quality of life at their initial assessment, and higher hospitalization rates over time, relative to idiopathic pulmonary arterial hypertension (IPAH) patients, according to a multicenter study in the U.S. Notably, these quality-of-life differences disappeared over time, and CTEPH…

Potential targets to treat pulmonary arterial hypertension (PAH) were identified by analyzing the gene activity of individual lung endothelial cells isolated from a mouse model of the disease. Study results were validated by cross-referencing them with rat and human gene activity datasets. “The identification of distinct molecular mechanisms and…

Children undergoing high-dose chemotherapy and hematopoietic stem cell transplant (HSCT) to treat their cancer should be screened for pulmonary arterial hypertension (PAH), according to a case report of two young patients at a Pennsylvania hospital. Its authors noted that other reports also suggested “possible links” between such treatments and PAH…